Tissium

Executive Summary

TISSIUM is a French medical technology company revolutionizing tissue reconstruction with its proprietary platform of biomorphic programmable polymers. Founded in 2013 and headquartered in Paris, the company addresses the persistent surgical challenge of reconstructing damaged tissue to restore natural function. With regulatory approval achieved, TISSIUM is poised to commercialize its innovative solutions, which offer advantages over traditional sutures and staples by enabling atraumatic, leak-proof sealing and promoting natural healing. The platform's versatility allows application across multiple surgical specialties, including vascular, hernia, and wound closure. TISSIUM's technology has the potential to reduce complications, shorten procedure times, and improve patient outcomes, positioning the company as a leader in regenerative medicine and medical devices.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of first product in European markets80% success
• Q4 2026FDA clearance for U.S. market entry60% success
• H2 2026Partnership with major surgical device distributor50% success